Skip to main content

Dementia with Lewy bodies

RewinD-LB

Leeftijd icoon
55+
Diagnose icoon
Dementia with Lewy bodies
Duratie onderzoek
Study days are spread over 21 to 55 weeks
Locatie icoon
Amsterdam, Den Bosch or Zwolle

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently. 

The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug are capsules that you take with food.

This study will try to determine if neflamapimod can improve memory and attention in people with Lewy bodies dementia. The study drug neflamapimod blocks a certain protein in the brain. This protein causes inflammation reaction in the brain which is stopped by the study drug. By blocking this protein there will be less damage in the brain and therefore there will be less memory and attention problems for people with DLB.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 9 times, spread over 21 weeks. After completing the main study, there is also an extension study you could participate in. If you participate in the extension study, you will visit the research center 6 more times, spread over 34 weeks. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 2 hours, others 1 hour. The research takes place in Amsterdam, Den Bosch or Zwolle. U can choose at which research center you participate.

This study is commissioned by EIP Pharma.

How does the application process go?

You always decide whether you participate in a study. Participation is always voluntary.

  1. You apply via the online form, this is non-binding.
  2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
  3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
  4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
  5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

What are the benefits of Brain Research Center?

  1. You always come first – everything we do revolves around you.
  2. Experienced team of doctors, neuropsychologists, and nurses.
  3. Open and homely atmosphere – this will make you feel relaxed and right at home.
  4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
  5. Always nearby – 3 locations spread through the Netherlands.

What's in it for me?

  • You may experience benefits from a new treatment.
  • You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
  • You make a meaningful contribution to a future without dementia with Lewy bodies.
  • You contribute to the advancement of science.

Can I participate?

You can participate when:

  • You are diagnosed with dementia with Lewy bodies
  • You are older than 55 years
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate. 

Take action against dementia with Lewy bodies. Sign up to participate.

Latest dementia with Lewy bodies trials

RewinD-LB
RewinD-LB

RewinD-LB

The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug are capsules that you take with food.

audience55+

levelDementia with Lewy bodies

durationStudy days are spread over 21 to 55 weeks

locationAmsterdam, Den Bosch or Zwolle